EGFR and adenocarcinoma: Even though better responsiveness has been observed in adenocarcinoma [34], especially for those with a higher presence of EGFR mutation, for whom this drug was designed in the first place [35], its clinical usage was very restricted due to its low response rate, high cost, and the fact that its recommended dosage is close to its maximum tolerated dose [36].